Abstract: Pleuromulin, also known as Pleuromutilin, is a broad-spectrum diterpene antibiotic derived from the fungus Pleurotus mutilus. This compound and its derivatives exhibit potent antibacterial activity against a wide range of Gram-positive bacteria, mycoplasmas, and some Gram-negative bacteria. This article explores the antimicrobial mechanism of Pleuromulin and traces its development history, highlighting key milestones and advancements in its synthesis and application.
Product Code: BM-2-5-121
English Name: Pleuromulin
CAS No.: 125-65-5
Molecular formula: C22H34O5
Molecular weight: 378.5
EINECS No.: 204-747-5
MDL No.：MFCD28154633
Analysis items: HPLC>99.0%, LC-MS
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Changzhou Factory
Technology service: R&D Dept.-4
We provide Pleuromulin CAS 125-65-5, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/api-researching-only/pleuromulin-cas-125-65-5.html
Keywords: Pleuromulin; antimicrobial mechanism; development history; Gram-positive bacteria; Pleurotus mutilus
Introduction
Antibiotics have been a cornerstone of modern medicine, enabling the effective treatment of bacterial infections. However, the rise of antibiotic resistance poses a significant threat to global health. The discovery and development of new antibiotics with novel mechanisms of action are crucial to combat this challenge. Pleuromulin, a diterpene antibiotic, represents one such promising candidate. This article delves into the antimicrobial mechanism of Pleuromulin and its development history, shedding light on its potential as a future therapeutic agent.
Antimicrobial Mechanism of Pleuromulin
Pleuromulin belongs to the pleuromutilin class of antibiotics, which are characterized by their unique chemical structure and mode of action. The antimicrobial activity of Pleuromulin is primarily attributed to its ability to inhibit bacterial protein synthesis, a crucial process for bacterial survival and replication.
|
|
|
Inhibition of Peptidyl Transferase
Pleuromulin exerts its antibacterial effect by targeting the peptidyl transferase center (PTC) of the bacterial ribosome. The ribosome is a complex molecular machine responsible for protein synthesis in all living cells. The PTC is a critical component of the ribosome, catalyzing the formation of peptide bonds between amino acids during protein elongation.
Pleuromulin binds to the PTC and inhibits its activity, thereby preventing the formation of peptide bonds and halting protein synthesis. This mechanism of action is distinct from that of other commonly used antibiotics, such as beta-lactams and macrolides, which target different aspects of bacterial cell wall synthesis or protein synthesis, respectively. The unique binding site of Pleuromulin on the ribosome makes it less susceptible to cross-resistance with other antibiotic classes, enhancing its potential as a treatment option for multidrug-resistant bacteria.
Broad-Spectrum Activity
Pleuromulin exhibits broad-spectrum antibacterial activity, effectively inhibiting the growth of various Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, and Enterococcus faecalis. It also shows activity against mycoplasmas and some Gram-negative bacteria, although its efficacy against the latter is generally lower.
The broad-spectrum activity of Pleuromulin can be attributed to the conservation of the ribosomal PTC across different bacterial species. By targeting a highly conserved and essential component of the bacterial machinery, Pleuromulin is able to exert its antimicrobial effect across a wide range of bacteria.
Resistance Mechanisms
Despite its unique mechanism of action, resistance to Pleuromulin has been observed in some bacterial strains. Resistance can arise through mutations in the ribosomal proteins or rRNA, which alter the binding site of Pleuromulin and reduce its affinity for the PTC. Additionally, efflux pumps, which are membrane-bound transporters that expel drugs from the cell, can also contribute to Pleuromulin resistance.
However, the rate of resistance development to Pleuromulin appears to be relatively low compared to other antibiotic classes. This may be due to the high fitness cost associated with mutations that confer resistance to Pleuromulin, as these mutations often affect essential ribosomal functions.
|
|
|
Development History of Pleuromulin
The development history of Pleuromulin spans several decades, marked by significant advancements in its isolation, synthesis, and clinical application.
Pleuromulin was first isolated in the 1950s from the fungus Pleurotus mutilus, a species of basidiomycete commonly found in soil and on decaying wood. The compound was initially identified as a secondary metabolite with potential antibacterial activity. Its unique chemical structure, characterized by a tricyclic diterpene skeleton with eight chiral centers, attracted considerable interest from researchers.
The isolation of Pleuromulin from natural sources proved to be challenging due to its low abundance in the fungus. However, advances in fermentation techniques and purification methods enabled the large-scale production of Pleuromulin for further research.
The complex structure of Pleuromulin posed significant challenges for its chemical synthesis. Early attempts at total synthesis were met with limited success, primarily due to the difficulty in controlling the stereochemistry of the multiple chiral centers. However, over the years, several research groups have developed efficient synthetic routes to Pleuromulin and its derivatives.
One notable approach involves the use of modular synthesis, where the complex molecule is constructed from simpler, pre-formed building blocks. This strategy has enabled the synthesis of a wide range of Pleuromulin analogs with varying degrees of antibacterial activity and pharmacological properties.
The development of catalytic asymmetric synthesis has also played a crucial role in the synthesis of Pleuromulin. These methods allow for the selective formation of chiral centers, ensuring the production of enantiomerically pure compounds. This is particularly important for Pleuromulin, as its biological activity is highly dependent on its stereochemistry.
The clinical development of Pleuromulin has been focused on its derivatives, rather than the parent compound itself. This is due to the poor pharmacokinetic properties of Pleuromulin, including low oral bioavailability and rapid metabolism.
One of the most successful derivatives of Pleuromulin is Retapamulin, a topical antibiotic approved for the treatment of impetigo and other skin infections caused by Gram-positive bacteria. Retapamulin is a C14-modified analog of Pleuromulin, designed to improve its pharmacological properties while retaining its potent antibacterial activity.
Other derivatives of Pleuromulin, such as Valnemulin and Tiamulin, have been developed for veterinary use. These compounds are used to treat respiratory and gastrointestinal infections in pigs and poultry, respectively. Their efficacy and safety in animals have led to their widespread use in the veterinary industry.
Despite the successes in the development of Pleuromulin derivatives, ongoing research continues to explore new analogs with improved properties. Researchers are particularly interested in developing compounds with enhanced activity against Gram-negative bacteria, as well as those with improved pharmacokinetic profiles for systemic use.
In addition, the unique mechanism of action of Pleuromulin has sparked interest in its potential as a lead compound for the development of novel antibiotics. By understanding the molecular interactions between Pleuromulin and the bacterial ribosome, researchers hope to design new compounds that target the same site but with improved potency and selectivity.
Conclusion
Pleuromulin, a diterpene antibiotic derived from the fungus Pleurotus mutilus, represents a promising candidate for the treatment of bacterial infections. Its unique mechanism of action, targeting the peptidyl transferase center of the bacterial ribosome, sets it apart from other antibiotic classes and reduces the risk of cross-resistance.
The development history of Pleuromulin has been marked by significant advancements in its isolation, synthesis, and clinical application. While the parent compound has limited pharmacokinetic properties, its derivatives have shown promise in both human and veterinary medicine.
Ongoing research continues to explore new analogs of Pleuromulin with improved properties, aiming to expand its therapeutic potential. The unique chemical structure and mode of action of Pleuromulin make it an attractive target for the development of novel antibiotics, particularly in the face of increasing antibiotic resistance.
As the global health community grapples with the challenge of antibiotic resistance, the discovery and development of new antibiotics with novel mechanisms of action are crucial. Pleuromulin and its derivatives represent one such avenue of research, offering hope for the future of antibacterial therapy.